The TAGGS CFDA Information Report provides detailed award information for a single CFDA Program. The data provided is from FY 2008 or from the start date of data collection through the present. For information prior to FY 2008, please use the TAGGS Advanced Search.
In the top display you will see the name of the CFDA program, agency, assistance type, and any popular name it might use, along with the 5-digit CFDA number.
CFDA Programs consisting of Direct Payment Awards may not contain links to additional recipient and award information. Direct Payment data is often collected as aggregated payments to a state to protect the personal information of the assistance recipients.
Along with the bar chart broken up by Issue Date or Funding Fiscal Year, there is also an exportable table below that groups by Issue Date or Funding Fiscal Year and shows the recipient name, state, award number, award title and amount from each award action.
By using the radio buttons, you may view data by the Issue Date Fiscal Year of by Funding Fiscal Year. In most cases, the Issue Date and Funding Fiscal Years coincide, although in some cases, delays in issuing an award and award close outs will cause the Issue Date of an award to be outside the of the Funding Fiscal Year.
Table data can be exported by choosing one of the export-format icons located at the top right of the table. Export file formats include:
The two Fiscal Year (FY) viewing options are:
|Issue Date FY||The FY in which the award action Occurred|
|Funding FY||The FY in which the award action Funded|
To enter Keyboard Support and Web Page Reader Support for the report results grid view, you will need to press Ctrl Shift G
|Move through rows||← ↑ ↓ →|
|Next page||SHIFT PAGE DOWN|
|Previous page||SHIFT PAGE UP|
|Move through column headers and data fields||TAB|
|Sort ASC/DESC when a column header is selected||ENTER|
Objectives: (1) To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic areas within the National Institute of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases. Specific programs areas of interest include the following: (a) For diabetes, endocrine, and metabolic diseases areas: Fundamental and clinical studies including the etiology, pathogenesis, prevention, diagnosis, treatment and cure of diabetes mellitus and its complications; Normal and abnormal function of the pituitary, thyroid, parathyroid, adrenal, and other hormone secreting glands; Hormonal regulation of bone, adipose tissue, and liver; on fundamental aspects of signal transduction, including the action of hormones, coregulators, and chromatin remodeling proteins; Hormone biosynthesis, secretion, metabolism, and binding; and on hormonal regulation of gene expression and the role(s) of selective receptor modulators as partial agonists or antagonists of hormone action; and Fundamental studies relevant to metabolic disorders including membrane structure, function, and transport phenomena and enzyme biosynthesis; and basic and clinical studies on the etiology, pathogenesis, prevention, and treatment of inherited metabolic disorders (such as cystic fibrosis). (b) For digestive disease and nutrition areas: Genetics and genomics of the GI tract and its diseases; Genetics and genomics of liver/pancreas and diseases; Genetics and genomics of nutrition; genetics and genomics of obesity; Bariatric surgery; Clinical nutrition research; Clinical obesity research; Complications of chronic liver disease; Fatty liver disease; Genetic liver disease; HIV and liver; Cell injury, repair, fibrosis and inflammation in the liver; Liver cancer; Liver transplantation; Pediatric liver disease; Viral hepatitis and infectious diseases; Gastrointestinal and nutrition effects of AIDS; Gastrointestinal mucosal and immunology; Gastrointestinal motility; Basic neurogastroenterology; Gastrointestinal development; Gastrointestinal epithelial biology; Gastrointestinal inflammation; Digestive diseases epidemiology and data systems; Nutritional epidemiology and data systems; Autoimmune liver disease; Bile, Bilirubin and cholestasis; Bioengineering and biotechnology related to digestive diseases, liver, nutrition and obesity; Cell and molecular biology of the liver; Developmental biology and regeneration; Drug-induced liver disease; Gallbladder disease and biliary diseases; Exocrine pancreas biology and diseases; Gastrointestinal neuroendocrinology; Gastrointestinal transport and absorption; Nutrient metabolism; Pediatric clinical obesity; Clinical trials in digestive diseases; Liver clinical trials; Obesity prevention and treatment; and Obesity and eating disorders. (c) For kidney, urologic and hematologic diseases areas: Studies of the development, physiology, and cell biology of the kidney; Pathophysiology of the kidney; Genetics of kidney disorders; Immune mechanisms of kidney disease; Kidney disease as a complication of diabetes; Effects of drugs, nephrotoxins and environmental toxins on the kidney; Mechanisms of kidney injury repair; Improved diagnosis, prevention and treatment of chronic kidney disease and end-stage renal disease; Improved approaches to maintenance dialysis therapies; Basic studies of lower urinary tract cell biology, development, physiology, and pathophysiology; Clinical studies of bladder dysfunction, incontinence, pyelonephritis, interstitial cystitis, benign prostatic hyperplasia, urolithiasis, and vesicoureteral reflux; Development of novel diagnostic tools and improved therapies, including tissue engineering strategies, for urologic disorders;Research on hematopoieti